Clinical Trials - Open

The clinical trials listed in this section are open to patient recruitment. For each trial, an overview of the study design is provided together with a brief explanation of the trial objectives. Members can review the Trial Report in the Members Area.

Filter AGITG trials by

LIBERATE

NSW | QLD | SA | TAS | VIC | WA

A phase II study evaluating liquid biopsies to profile metastatic colorectal cancer. Read More

MODULATE

NSW | QLD | SA | TAS | VIC

Modulation of the tumour microenvironment using either vascular disrupting agents or STAT3 inhibition in order to synergise with PD1 inhibition in microsatellite stable, refractory colorectal cancer. Read More

DYNAMIC – Rectal

NSW | VIC

This study aims to demonstrate that a chemotherapy decision incorporating ctDNA results in addition to standard pathologic risk assessment will reduce the number of patients receiving adjuvant chemotherapy. Read More

DYNAMIC III

NSW | QLD | TAS | VIC | WA | New Zealand

The purpose of the DYNAMIC-III study is to determine that a chemotherapy decision based on the presence or absence of circulating tumour DNA after surgery for stage III colorectal cancer, will be more effective than standard of care treatment as measured by how many patients remain cancer free at 3 years. Read More

ACTICCA-1

NSW | QLD | SA | WA

The aim of ACTICCA-1 is to determine whether treating patients with chemotherapy following surgery for cancer of the biliary tract helps to reduce cancer recurrence. Read More

TOPGEAR

NSW | QLD | SA | TAS | VIC | WA | New Zealand

The purpose of TOPGEAR is to investigate the benefit of adding radiation (chemoradiotherapy) to chemotherapy and surgery to treat and improve the overall survival in patients undergoing surgery for resectable stomach cancer. Read More

NABNEC

NSW | QLD | SA | TAS | VIC | WA | New Zealand

The aim of NABNEC is to determine the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with the current standard chemotherapy treatment plan (carboplatin plus etoposide) for advanced gastrointestinal neuroendocrine carcinomas (NECs). Read More

ASCOLT

NSW | NT | QLD | SA | TAS | VIC | WA | New Zealand

The ASCOLT study will evaluate the safety and effectiveness of low-dose aspirin compared to placebo in reducing recurrence of colorectal cancer and improving survival for patients with Dukes C and high-risk Dukes B colorectal cancer. Read More

SPAR

NSW | SA | New Zealand

This randomised phase II trial aims to evaluate the effect of simvastatin (SIM) on efficacy and toxicity of pCRT in rectal cancer patients, and on systemic and local inflammatory responses. Read More

MONARCC

NSW | QLD | SA | TAS | VIC

The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer. Read More

INTEGRATE II

ACT | NSW | NT | QLD | SA | TAS | VIC | WA | New Zealand

The purpose of INTEGRATE II is to determine whether Regorafenib is effective in prolonging survival in patients with Advanced Gastro-Oesophageal Carcinoma (AGOC). Read More